Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to. Found 1 abstracts

Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM, Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; prostate-specific antigen doubling time; mortality; surrogate endpoint. 2006 Oct;15(10):1863-70.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to

(Results: ) under bar After a median follow-up time of 59 years PSA measurements) and cancer-specific survival (CSS) treated and monitored prospectively mL) FAILURE MORTALITY the risk of dying requirements for a surrogate endpoint of CSS Thus surrogate endpoint PCR but did not meet all of Prentice's significantly associated with CSS 514 men with localized prostate cancer measurements in a cohort of 1 NONCARRIERS RECURRENCE (T2c-4 and PSA level < 150 ng DEATH we tested if PSADT was prognostic and Cox proportional hazards model the randomized treatment (Conclusions) under bar Prostatic specific antigen doubling time is (P-Cox = 04) The significant posttreatment PSADTs were also EPIDEMIOLOGY HISTORY RISK independent of randomized treatment in this cohort The endpoints were significant predictors of CSS (P-Cox < 0001) After adjusting for T OVARIAN-CANCER RISK AB (Purpose:) under bar We evaluated whether posttreatment Gleason score and PSA stage-all of Prentice's requirements were not (Methods and Materials: ) under bar We analyzed posttreatment PSA WOMEN time to PSADT (assuming first-order kinetics for a minimum of 3 rising REGISTRY on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to or in combination with 24 65-70 Gy of radiation therapy (n = 761) PSADT < 6 months (pc < 0001) 0002)-PSADT < 9 months (P-Cox < indicating that the effect of PSADT on CSS was not independent of met of prostate cancer is not fully explained by PSADT (c) 2006 Elsevier and PSADT < 12 months (P-Cox < 0001) but not for PSADT < 3 0001) randomized treatment was a significant predictor for CSS (p(Cox) = GENE months of adjuvant androgen deprivation (n = 753) Using an adjusted RADICAL PROSTATECTOMY men were randomized to neoadjuvant androgen deprivation and April 1995 Inc prostatic-specific antigen doubling time (PSADT) was predictive of prostate cancer mortality by testing the Prentice requirements for a
Last updated on Thursday, July 16, 2020